Detalles de la búsqueda
1.
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
J Hepatol
; 65(2): 289-95, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27085251
2.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153538
3.
The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Cancers (Basel)
; 16(1)2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38201506
4.
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.
Oncotarget
; 9(12): 10436-10444, 2018 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29535817
5.
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Cancer Chemother Pharmacol
; 79(2): 421-429, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28120036
Resultados
1 -
5
de 5
1
Próxima >
>>